123685-57-4

Basic information

• Product Name: Prop-2-ynyl-(3,4,5-trimethoxy-phenyl)-amine
• Synonyms: Prop-2-ynyl-(3,4,5-trimethoxy-phenyl)-amine
• CAS NO: 123685-57-4
• Molecular Weight: 221.256
• Mol File: 123685-57-4.mol

Chemical Properties

• CAS DataBase Reference: Prop-2-ynyl-(3,4,5-trimethoxy-phenyl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: Prop-2-ynyl-(3,4,5-trimethoxy-phenyl)-amine(123685-57-4)
• EPA Substance Registry System: Prop-2-ynyl-(3,4,5-trimethoxy-phenyl)-amine(123685-57-4)

Safety Data

• Hazardous Substances Data: 123685-57-4(Hazardous Substances Data)

Upstream product

• 106-96-7 propargyl bromide 
• 24313-88-0 3,4,5-Trimethoxyaniline 

Downstream Products

• 206561-41-3 2,2-Dimethyl-N-(3-phenyl-7-{[prop-2-ynyl-(3,4,5-trimethoxy-phenyl)-amino]-methyl}-quinoxalin-2-yl)-propionamide 
• 123685-32-5 2-amino-6-[[2-propynyl(3,4,5-trimethoxyphenyl)amino]methyl]-4(3H)-quinazolinone 
• 123685-42-7 <4-oxo-6-<<2-propynyl(3,4,5-trimethoxyphenyl)amino>methyl>-3(4H)-quinazolinyl>methyl 2,2-dimethylpropanoate 
• 123685-28-9 6-[[2-Propynyl-(3,4,5-trimethoxyphenyl)amino]methyl]-4(3H)-quinazolinone 

Relevant articles and documents

6-Substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents

The synthesis and biological activity of 15 6-substituted 2,4-diamino-5- methylpyrido[2,3-d]-pyrimidines are reported. These compounds were synthesized in improved yields by modifications of procedures previously reported by us. Specifically, dimethoxyphe

AgNO2 as the NO Source for the Synthesis of Substituted Pyrazole N-Oxides from N-Propargylamines

A straightforward method for synthesizing the pyrazole N-oxides from N-propargylamines and AgNO2 through oxidation/cyclization reaction had been developed. AgNO2 was used as the NO source for the first time to synthesize pyrazole N-o

Synthesis and evaluation of novel fluorinated pyrazolo-1,2,3-triazole hybrids as antimycobacterial agents

A library of novel 3-trifluoromethyl pyrazolo-1,2,3-triazole hybrids (5-7) were accomplished starting from 5-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-amine (1) via key intermediate 2-azido-N-(5-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)acetamide (3) throu

2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes

Based on our previous results on the ascertained potent growth inhibition effect against a panel of 60 human tumors cell lines at National Cancer Institute of Bethesda (NCI), we have synthesized a novel series of thirty-one 2-[N-methyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines (1-31). The lead compound 1 was previously reported to be endowed with significant inhibition against hDHFR enzyme, with a Ki of 0.2 μM. Docking studies were performed on compound 1 and here reported to predict its binding conformation to human dihydrofolate reductase (hDHFR). All compounds (1-31) were assayed versus hDHFR and human thymidylate synthase (hTS). From the screening emerged that all compounds inhibited hDHFR with Ki values included between 0.2 and 11 μM, while only a few (6, 21, 24, 27, 29) showed great activity and selectivity towards hTS. Evaluation of the anticancer activity was performed by NCI, first against the three cell line panel, and only the most active compounds (17, 21, 24, 26, 27) were evaluated on a panel of 60 human tumor cell lines. Compound 21 was the most active against all cell lines with log GI50 equal to -5.49 and log LC50 equal to -4.19 and maintained significant percent of growth inhibition on seven cancer cell lines at the concentration of 1 μM. Compound 17 was the second most active and moreover showed interesting selectivity against some cell lines (Lung cancer: A549/ATCC, Melanoma: UACC-257, Ovarian Cancer: ovcar-8 and Renal cancer: RXF 393) at all concentration examined (100-0.01 μM).

Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines

The synthesis and biological activity of two series of nonclassical thymidylate synthase (TS) inhibitors are described. The first is a series of 10-propargyl-5.8-dideazafolic acid derivatives (10a-j) and the second is a series of the analogous 2-desamino